A new therapy “likely to change the face of prostate cancer treatment” for men should be funded for public patients, according to almost 40 cancer consultants.

Consultants wrote to HSE CEO Bernard Gloster asking for negotiations with the makers of Pluvicto to continue. It benefits men with advanced metastatic prostate cancer. It was approved in France earlier this week and is used across eight EU countries and elsewhere.

UCAN have also urged Bernard Gloster and the HSE to reconsider this decision